Watson Moves To Undo Amarin's Exclusivity Win Over FDA
Watson Laboratories Inc. on Wednesday moved to eliminate extra exclusivity granted recently for Amarin Pharmaceuticals Ireland Ltd.'s omega-3 drug Vascepa, appealing to the D.C. Circuit and asking for permission to take...To view the full article, register now.
Already a subscriber? Click here to view full article